CLMH Hydrogel Sustained PTH Release for Osteoarthritis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoarthritis using parathyroid hormone (PTH) require frequent administration, leading to patient discomfort and low bioavailability, as existing delivery methods fail to maintain therapeutic levels effectively for an extended period.
Innovation Solution
A cross-linked methacrylated-hyaluronic acid (CLMH) hydrogel is used to encapsulate PTH(1-34), allowing for controlled release over at least 10 days when injected intra-articularly, maintaining effective concentrations and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PTH(1-34) is administered by frequent subcutaneous injection, then therapeutic effect is achieved, but patient compliance deteriorates due to discomfort and inconvenience
Solution Approach 1:
A hydrogel carrier system is introduced as an intermediary between the PTH drug and the patient's body. The hydrogel encapsulates PTH(1-34) and enables sustained local delivery to the joint, eliminating the need for frequent injections while maintaining therapeutic efficacy. This mediator resolves the contradiction by providing a convenient single or infrequent administration route that achieves reliable therapeutic outcomes.
Solution Approach 2:
The hydrogel formulation provides continuous release of PTH(1-34) over an extended period (at least 10 days) following a single injection. This continuous delivery mechanism maintains therapeutic levels of the drug without requiring repeated administrations, thereby improving patient compliance while ensuring reliable therapeutic effect throughout the treatment period.
2Ease of operation
If PTH(1-34) is administered orally, then patient compliance improves, but bioavailability deteriorates to only 5% and 2.1%
Solution Approach 1:
The hydrogel acts as a protective intermediary carrier that shields PTH(1-34) from degradation in the gastrointestinal tract during oral administration. By encapsulating the peptide drug within the hydrogel matrix, the system enables oral delivery while preserving drug stability and achieving sufficient bioavailability, thus resolving the contradiction between administration convenience and drug effectiveness.
3Reliability
If PTH(1-34) is administered via pulmonary route, then bioavailability improves to 40% and 34%, but device complexity increases due to specialized delivery equipment requirements
Solution Approach 1:
The invention employs a simple, disposable hydrogel formulation that can be administered via basic injection techniques. This eliminates the need for complex pulmonary delivery equipment such as inhalers or nebulizers. The hydrogel provides sustained release functionality through its material properties alone, resolving the contradiction by achieving reliable drug delivery with minimal device complexity.
4Ease of operation
If injection interval is prolonged, then patient compliance improves, but therapeutic level maintenance deteriorates
Solution Approach 1:
The hydrogel formulation ensures continuous release of PTH(1-34) at therapeutic levels over an extended period of at least 10 days following a single injection. This continuous action profile maintains effective drug concentrations throughout the prolonged interval between administrations, resolving the contradiction by enabling both improved patient compliance and reliable therapeutic level maintenance.
Solution Approach 2:
The hydrogel system provides dynamic control of drug release, adjusting the release rate to maintain therapeutic levels over time. The formulation delivers higher initial concentrations followed by sustained lower concentrations, optimizing both immediate therapeutic effect and prolonged maintenance, thereby enabling prolonged injection intervals while ensuring continuous therapeutic efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CLMH hydrogel effectively delivers PTH(1-34) for an extended period, maintaining therapeutic levels and bioactivity, thereby reducing the frequency of injections and improving treatment compliance and efficacy in osteoarthritis management.
Implementation Method 1
controlled release of an effective amount of PTH for at least 10 days
Implementation Method 2
cross-linked methacrylated-hyaluronic acid (CLMH) hydrogel
Implementation Method 3
cross-linked methacrylated-hyaluronic acid (CLMH) hydrogel
Data Source
AI summary
A method for locally controlled release of an effective amount of PTH(1-34) by a hyaluronic acid based hydrogel that can injected intra-articularly for the treatment of osteoarthritis is provided.